We could not find any results for:
Make sure your spelling is correct or try broadening your search.
LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today...
14-month data show treatment with setrusumab resulted in a large, sustained 67% reduction in annualized fracture rate and persistent median annualized fracture rate of 0.00 (p=0.0014) Treatment...
LONDON, May 30, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0.85 | 0.8575 | 0.85 | 41797 | 0.85 | DE |
26 | 0 | 0 | 0.65 | 1.05 | 0.65 | 333235 | 0.89347693 | DE |
52 | 0 | 0 | 1.75 | 3.75 | 0.65 | 280619 | 1.00052769 | DE |
156 | 0 | 0 | 9.5 | 9.5 | 0.65 | 106743 | 1.94190134 | DE |
260 | 0 | 0 | 7.5 | 13.5 | 0.65 | 79835 | 3.57922875 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions